Unknown

Dataset Information

0

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.


ABSTRACT:

Background

Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL.

Materials and methods

We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed.

Results

The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively.

Conclusion

PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.

SUBMITTER: Pinnix CC 

PROVIDER: S-EPMC9754636 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL.<h4>Materials and methods</h4>We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity  ...[more]

Similar Datasets

| S-EPMC5016012 | biostudies-literature
| S-EPMC9699755 | biostudies-literature
| S-EPMC10111342 | biostudies-literature
| S-EPMC3932020 | biostudies-literature
| S-EPMC3227958 | biostudies-literature
| S-EPMC9545967 | biostudies-literature
| S-EPMC6467349 | biostudies-literature
| S-EPMC10905319 | biostudies-literature
| S-EPMC9754637 | biostudies-literature